[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on�…
JM Jones�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
[HTML][HTML] Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First�…
HL Moline�- MMWR. Morbidity and mortality weekly report, 2024 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the
United States. In August 2023, CDC's Advisory Committee on Immunization Practices�…
United States. In August 2023, CDC's Advisory Committee on Immunization Practices�…
[HTML][HTML] Single-dose nirsevimab for prevention of RSV in preterm infants
MP Griffin, Y Yuan, T Takas…�- …�England Journal of�…, 2020 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the most common cause of lower
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy�…
respiratory tract infection in infants, and a need exists for prevention of RSV in healthy�…
Nirsevimab for prevention of RSV in healthy late-preterm and term infants
LL Hammitt, R Dagan, Y Yuan…�- …�England Journal of�…, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV�…
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV�…
[HTML][HTML] Nirsevimab for prevention of hospitalizations due to RSV in infants
SB Drysdale, K Cathie, F Flamein, M Knuf…�- …�England Journal of�…, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
Nirsevimab for prevention of RSV in term and late-preterm infants
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced�…
Medicine Skip to main content The New England Journal of Medicine homepage Advanced�…
Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model
A Kieffer, M Beuvelet, A Sardesai…�- The Journal of�…, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting�…
United States, especially among infants. Nirsevimab, an investigational long-acting�…
Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity
J Domachowske, SA Madhi, EAF Sim�es…�- …�England Journal of�…, 2022 - Mass Medical Soc
Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to�…
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to�…
Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis
M Sun, H Lai, F Na, S Li, X Qiu, J Tian…�- JAMA Network�…, 2023 - jamanetwork.com
Importance Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory
infection in children younger than 5 years; effective prevention strategies are urgently�…
infection in children younger than 5 years; effective prevention strategies are urgently�…
Nirsevimab and hospitalization for RSV bronchiolitis
Z Assad, AS Romain, C Aupiais, M Shum…�- …�England Journal of�…, 2024 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…
Related searches
- immunization practices young children
- advisory committee young children
- immunization practices advisory committee
- nirsevimab for the prevention young children
- immunization practices nirsevimab for the prevention
- advisory committee nirsevimab for the prevention
- universal immunization rsv season
- outcomes and costs rsv season
- monoclonal antibody infants and children
- expected impact rsv season
- meta analysis infants and children
- monoclonal antibody meta analysis
- prevention of hospitalizations rsv in infants
- nirsevimab for rsv lung disease
- rsv prevention updated recommendations
- lung disease rsv in infants